3 research outputs found
The travails of therapeutic modifications in cancer care amidst the COVID-19 pandemic: future directions and lessons learned
The coronavirus disease 2019 (COVID-19) pandemic continues to
pose challenges of unparalleled magnitude. Unsurprisingly, COVID-19
amongst cancer patients has been associated with higher mortality
rates and ventilation support, with the highest mortality associated with
hematological malignancies [1–3]. The burgeoning risk of disease progression secondary to delayed treatment-seeking behavior precipitated
by fears surrounding the pandemic has resulted in significant morbidity
and mortality. While the risk stratification and categorization of cancer
care priority remains elusive, we hereby provide some suggestions to
bridge the chasm that exists in our current cancer care regimens despite
recent suggestions pertaining to therapeutic modifications. <br